BlackRock Fund Advisors’s Endocyte, Inc. Common Stock ECYT Stock Holding History

BlackRock Fund Advisors’s Portfolio ECYT Stock Details ECYT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$3.26M	Sell	1,280,030 -418,434	-25%	-$1.2M	﹤0.01%	3060
2016 Q3	$5.25M	Buy	1,698,464 +137,032	+9%	+$427K	﹤0.01%	2823
2016 Q2	$5.01M	Buy	1,561,432 +52,481	+3%	+$192K	﹤0.01%	2805
2016 Q1	$4.68M	Buy	1,508,951 +52,051	+4%	+$170K	﹤0.01%	2778
2015 Q4	$5.84M	Sell	1,456,900 -106,665	-7%	-$491K	﹤0.01%	2752
2015 Q3	$7.16M	Buy	1,563,565 +54,956	+4%	+$288K	﹤0.01%	2572
2015 Q2	$7.83M	Sell	1,508,609 -61,159	-4%	-$367K	﹤0.01%	2645
2015 Q1	$9.83M	Buy	1,569,768 +17,524	+1%	+$101K	﹤0.01%	2454
2014 Q4	$9.76M	Buy	1,552,244 +146,971	+10%	+$896K	﹤0.01%	2472
2014 Q3	$8.54M	Buy	1,405,273 +6,199	+0.4%	+$42.3K	﹤0.01%	2448
2014 Q2	$9.22M	Buy	1,399,074 +100,506	+8%	+$1.13M	﹤0.01%	2470
2014 Q1	$30.9M	Buy	1,298,568 +55,098	+4%	+$799K	0.01%	1743
2013 Q4	$13.3M	Sell	1,243,470 -15,089	-1%	-$167K	﹤0.01%	2213
2013 Q3	$16.8M	Buy	1,258,559 +164,302	+15%	+$2.6M	0.01%	2059
2013 Q2	$14.4M	Buy	+1,094,257	New	+$14.8M	0.01%	2043

Other funds holding ECYT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Pinnacle Associates New York $7.78B AUM 45.07% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

HCMT

Highland Capital Management (Texas) Dallas, Texas $39M AUM

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

BlackRock Fund Advisors's ECYT Position: Q4 2016 in Review

BlackRock Fund Advisors reduced its Endocyte, Inc. Common Stock (ECYT) stake by 25% in Q4 2016, selling an estimated $1.2M and leaving 1,280,030 shares worth $3.26M. The position accounts for ﹤0.01% of the portfolio, ranked #3060.

BlackRock Fund Advisors first reported a position in ECYT in Q2 2013 and has held it in 15 quarters since. The position peaked at $30.9M in Q1 2014. 96 funds tracked by Wall St. Rank hold ECYT as of Q4 2016.

BlackRock Fund Advisors held 1,280,030 shares of Endocyte, Inc. Common Stock worth $3.26M as of Q4 2016.
BlackRock Fund Advisors sold 418,434 Endocyte, Inc. Common Stock shares in Q4 2016, an estimated $1.2M.
Endocyte, Inc. Common Stock made up ﹤0.01% of BlackRock Fund Advisors's portfolio in Q4 2016, its #3060 holding.
BlackRock Fund Advisors first reported a position in Endocyte, Inc. Common Stock in Q2 2013 and has held it in 15 quarters since.
BlackRock Fund Advisors's Endocyte, Inc. Common Stock position peaked at $30.9M in Q1 2014.
96 funds tracked by Wall St. Rank held Endocyte, Inc. Common Stock as of Q4 2016.

Based on BlackRock Fund Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.